Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients.
Boursier J, Ducancelle A, Vergniol J, Veillon P, Moal V, Dufour C, Bronowicki JP, Larrey D, Hézode C, Zoulim F, Fontaine H, Canva V, Poynard T, Allam S, De Lédinghen V; ANRS CO20 CUPIC Study Group. Boursier J, et al. Among authors: hezode c. J Viral Hepat. 2015 Dec;22(12):1002-10. doi: 10.1111/jvh.12433. Epub 2015 Jul 27. J Viral Hepat. 2015. PMID: 26216230
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study.
Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, Trimoulet P, Couzigou P, Cointe D, Chaput C, Henquell C, Abergel A, Pawlotsky JM, Hezode C, Coudé M, Blanchi A, Alain S, Loustaud-Ratti V, Chevallier P, Trepo C, Gerolami V, Portal I, Halfon P, Bourlière M, Bogard M, Plouvier E, Laffont C, Agius G, Silvain C, Brodard V, Thiefin G, Buffet-Janvresse C, Riachi G, Grattard F, Bourlet T, Stoll-Keller F, Doffoel M, Izopet J, Barange K, Martinot-Peignoux M, Branger M, Rosenberg A, Sogni P, Chaix ML, Pol S, Thibault V, Opolon P, Charrois A, Serfaty L, Fouqueray B, Grange JD, Lefrère JJ, Lunel-Fabiani F. Payan C, et al. Among authors: hezode c. J Viral Hepat. 2005 Jul;12(4):405-13. doi: 10.1111/j.1365-2893.2005.00605.x. J Viral Hepat. 2005. PMID: 15985012
Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study.
Bonny C, Fontaine H, Poynard T, Hézode C, Larrey D, Marcellin P, Bourlière M, Bronowicki JP, Merle P, Zarski JP, Sapey T, Guillemard C, Ughetto S, Henquell C, Nicolas C, Roche C, Randl K, Bommelaer G, Abergel A. Bonny C, et al. Among authors: hezode c. Aliment Pharmacol Ther. 2006 Aug 15;24(4):593-600. doi: 10.1111/j.1365-2036.2006.03018.x. Aliment Pharmacol Ther. 2006. PMID: 16907892 Free article.
Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.
Abergel A, Hezode C, Leroy V, Barange K, Bronowicki JP, Tran A, Alric L, Castera L, Bernard PH, Henquell C, Lafeuille H, Ughetto S, Darcha C, Chevallier M, Martineau N, Dubost S, Randl K, Dhumeaux D, Bommelaer G, Bonny C; French multicenter study group. Abergel A, et al. Among authors: hezode c. J Viral Hepat. 2006 Dec;13(12):811-20. doi: 10.1111/j.1365-2893.2006.00768.x. J Viral Hepat. 2006. PMID: 17109680 Clinical Trial.
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S; PROVE2 Study Team. Hézode C, et al. N Engl J Med. 2009 Apr 30;360(18):1839-50. doi: 10.1056/NEJMoa0807650. N Engl J Med. 2009. PMID: 19403903 Free article. Clinical Trial.
Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy.
Legrand-Abravanel F, Colson P, Leguillou-Guillemette H, Alric L, Ravaux I, Lunel-Fabiani F, Bouviers-Alias M, Trimoulet P, Chaix ML, Hézode C, Foucher J, Fontaine H, Roque-Afonso AM, Gassin M, Schvoerer E, Gaudy C, Roche B, Doffoël M, D'Alteroche L, Vallet S, Baazia Y, Pozzetto B, Thibault V, Nousbaum JB, Roulot D, Coppere H, Poynard T, Payan C, Izopet J. Legrand-Abravanel F, et al. Among authors: hezode c. J Med Virol. 2009 Dec;81(12):2029-35. doi: 10.1002/jmv.21583. J Med Virol. 2009. PMID: 19856464 Free article.
IL28B polymorphisms and chronic hepatitis C.
Chevaliez S, Hézode C. Chevaliez S, et al. Among authors: hezode c. Gastroenterol Clin Biol. 2010 Nov;34(11):587-9. doi: 10.1016/j.gcb.2010.06.008. Gastroenterol Clin Biol. 2010. PMID: 20889274 Free article. Review.
High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).
Chevaliez S, Hézode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM. Chevaliez S, et al. Among authors: hezode c. Gastroenterology. 2011 Jul;141(1):119-27. doi: 10.1053/j.gastro.2011.03.039. Epub 2011 Mar 24. Gastroenterology. 2011. PMID: 21439960 Free article. Clinical Trial.
192 results